Search Results - "Bhatt, Amit R"

Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity by Wallace, David K, Kraker, Raymond T, Freedman, Sharon F, Crouch, Eric R, Bhatt, Amit R, Hartnett, M Elizabeth, Yang, Michael B, Rogers, David L, Hutchinson, Amy K, VanderVeen, Deborah K, Haider, Kathryn M, Siatkowski, R Michael, Dean, Trevano W, Beck, Roy W, Repka, Michael X, Smith, Lois E, Good, William V, Kong, Lingkun, Cotter, Susan A, Holmes, Jonathan M

“…Intravitreous bevacizumab (0.25 mg to 0.625 mg) is commonly used to treat type 1 retinopathy of prematurity (ROP), but there are concerns about systemic…”
Get more information

Timely recognition of retinal hemorrhage in pediatric abusive head trauma evaluation by Burge, Lauren R., Van Horne, Bethanie S., Bachim, Angela, Bhatt, Amit R., Donaruma, Marcella

“…Distinct patterns of retinal hemorrhages (RHs) are suggestive of abusive head trauma in the context of unexplained intracranial injury. Current recommendations…”
Get full text

Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity by Kong, Lingkun, Bhatt, Amit R, Demny, Ann B, Coats, David K, Li, Alexa, Rahman, Effie Z, Smith, O'Brian E, Steinkuller, Paul G

“…To measure serum levels of bevacizumab and to compare serum levels of free vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1)…”
Get full text

Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study by Wallace, David K, Kraker, Raymond T, Freedman, Sharon F, Crouch, Eric R, Hutchinson, Amy K, Bhatt, Amit R, Rogers, David L, Yang, Michael B, Haider, Kathryn M, VanderVeen, Deborah K, Siatkowski, R Michael, Dean, Trevano W, Beck, Roy W, Repka, Michael X, Smith, Lois E, Good, William V, Hartnett, Mary Elizabeth, Kong, Lingkun, Holmes, Jonathan M

“…Intravitreous bevacizumab (0.25 to 0.625 mg) is increasingly used to treat type 1 retinopathy of prematurity (ROP), but there remain concerns about systemic…”
Get more information

Overminus Lens Therapy for Children 3 to 10 Years of Age With Intermittent Exotropia: A Randomized Clinical Trial by Chen, Angela M, Erzurum, S Ayse, Chandler, Danielle L, Hercinovic, Amra, Melia, B Michele, Bhatt, Amit R, Suh, Donny W, Vricella, Marilyn, Erickson, John W, Miller, Aaron M, Marsh, Justin D, Bodack, Marie I, Martinson, Stacy R, Titelbaum, Jenna R, Gray, Michael E, Holtorf, Hannah L, Kong, Lingkun, Kraker, Raymond T, Rahmani, Bahram, Shah, Birva K, Holmes, Jonathan M, Cotter, Susan A

“…This is the first large-scale randomized clinical trial evaluating the effectiveness and safety of overminus spectacle therapy for treatment of intermittent…”
Get more information

Use of an Artificial Intelligence-Generated Vascular Severity Score Improved Plus Disease Diagnosis in Retinopathy of Prematurity by Coyner, Aaron S., Young, Benjamin K., Ostmo, Susan R., Grigorian, Florin, Ells, Anna, Hubbard, Baker, Rodriguez, Sarah H., Rishi, Pukhraj, Miller, Aaron M., Bhatt, Amit R., Agarwal-Sinha, Swati, Sears, Jonathan, Chan, R. V. Paul, Chiang, Michael F., Kalpathy-Cramer, Jayashree, Binenbaum, Gil, Campbell, J. Peter

“…To evaluate whether providing clinicians with an artificial intelligence (AI)-based vascular severity score (VSS) improves consistency in the diagnosis of plus…”
Get full text

Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity Infants by Kong, Lingkun, Demny, Ann B, Sajjad, Ahmar, Bhatt, Amit R, Devaraj, Sridevi

“…We compared changes of plasma angiogenesis cytokine profiles in infants who were treated with intravitreal injection of bevacizumab (IVB) for type 1…”
Get full text

Clinical Pearl: The "Rule of 8" by Shen, Kevin Lu, Bhatt, Amit R

“…Preschool-aged children typically perform worse than 20/20 on visual acuity testing in the absence of ocular or visual pathway abnormalities due to non-ocular…”
Get full text

Retinopathy of Prematurity: Injection or Laser by Bhatt, Amit R, Jordan, Catherine O, Wagner, Rudolph S

“…Bhatt: Based on that history and the age, I would lean toward intravitreal anti-vascular endothelial growth factor (VEGF) treatments over laser in this case…”
Get full text

Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity by Wallace, David K., Hercinovic, Amra, Freedman, Sharon F., Crouch, Eric R., Bhatt, Amit R., Hartnett, M. Elizabeth, Yang, Michael B., Rogers, David L., Hutchinson, Amy K., Good, William V., Repka, Michael X., Li, Zhuokai, Beck, Roy W., Kraker, Raymond T., Cotter, Susan A., Holmes, Jonathan M.

“…To report 2-year ocular and developmental outcomes for infants receiving low doses of intravitreal bevacizumab for type 1 retinopathy of prematurity (ROP). A…”
Get full text

Treatment of type 1 retinopathy of prematurity with 0.25 mg intravitreal bevacizumab by Kang, Terry S, Ram, Radha, Bhatt, Amit R

Get full text

Middle Ear Effusion in Children With Congenital Cytomegalovirus Infection by Chung, Winnie, Leung, Jessica, Lanzieri, Tatiana M., Blum, Peggy, Demmler-Harrison, Gail

“…BACKGROUND:Sensorineural hearing loss (SNHL) is well described in children with congenital cytomegalovirus (CMV) infection, but limited data are available on…”
Get full text

Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy by Lanzieri, Tatiana M, Caviness, Alison Chantal, Blum, Peggy, Demmler-Harrison, Gail

“…Abstract Background Long-term hearing outcomes among children with symptomatic congenital cytomegalovirus (CMV) disease who received 6-week ganciclovir therapy…”
Get full text

Management of Recurrent Retinopathy of Prematurity Following Anti-VEGF Injection by Bhatt, Amit R, Paul Chan, R V, Reynolds, James D, Wagner, Rudolph S

“…Reynolds: The bottom line is that we do not know the natural history of ROP after anti-vascular endothelial growth factor (VEGF) treatment. Is it going to have…”
Get full text

Clinical efficacy and pharmacology of bevacizumab in treatment of retinopathy of prematurity (ROP): a comparison of two dosages by Kong, Lingkun, Bhatt, Amit R, Demny, Ann B, Coats, David K, Steinkuller, Paul G

Get full text

Cortical Visual Impairment in Congenital Cytomegalovirus Infection by Jin, Haoxing Douglas, Demmler-Harrison, Gail J, Miller, Jerry, Edmond, Jane C, Coats, David K, Paysse, Evelyn A, Bhatt, Amit R, Yen, Kimberly G, Klingen, Joseph T, Steinkuller, Paul

“…To describe the presentation, evolution, and long-term outcome of cortical visual impairment (CVI) in patients with symptomatic congenital cytomegalovirus…”
Get full text

Hearing Loss in Children With Asymptomatic Congenital Cytomegalovirus Infection by Lanzieri, Tatiana M, Chung, Winnie, Flores, Marily, Blum, Peggy, Caviness, A Chantal, Bialek, Stephanie R, Grosse, Scott D, Miller, Jerry A, Demmler-Harrison, Gail

“…To assess the prevalence, characteristics, and risk of sensorineural hearing loss (SNHL) in children with congenital cytomegalovirus infection identified…”
Get full text

Two-year ocular and developmental outcomes of a phase 1 dosing study of bevacizumab for retinopathy of prematurity by Wallace, David K., Hercinovic, Amra, Freedman, Sharon F., Crouch, Eric R., Bhatt, Amit R., Hartnett, M. Elizabeth, Yang, Michael B., Rogers, David L., Hutchinson, Amy K., Good, William V., Repka, Michael X., Kraker, Raymond T., Cotter, Susan A., Holmes, Jonathan M.

Get full text

Long-term outcomes of children with symptomatic congenital cytomegalovirus disease by Lanzieri, T M, Leung, J, Caviness, A C, Chung, W, Flores, M, Blum, P, Bialek, S R, Miller, J A, Vinson, S S, Turcich, M R, Voigt, R G, Demmler-Harrison, G

“…Objective: To assess long-term outcomes of children with symptomatic congenital cytomegalovirus (CMV) disease detected at birth. Study Design: We used Cox…”
Get full text

A randomized trial evaluating effectiveness of overminus spectacles in children 3 to 10 years of age with intermittent exotropia by Chen, Angela M., Erzurum, Sergul A., Chandler, Danielle L., Hercinovic, Amra, Melia, B. Michele, Bhatt, Amit R., Suh, Donny W., Vricella, Marilyn, Erickson, John W., Miller, Aaron M., Marsh, Justin D., Bodack, Marie I., Martinson, Stacy R., Titelbaum, Jenna R., Gray, Michael E., Holtorf, Hannah L., Kong, Lingkun, Kraker, Raymond T., Rahmani, Bahram, Shah, Birva K., Holmes, Jonathan M., Cotter, Susan A.

Get full text